Treatment options for myelodysplastic syndromes.
Stone
Richard
R
Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA 02115, USA. rstone@partners.org
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy*; D011994:Recombinant Proteins; D013792:Thalidomide / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D013792:Thalidomide; D001374:Azacitidine